Key result
The combination of vildagliptin and ischemic postconditioning significantly reduced myocardial infarct size by up to 48.18% compared to diabetic control in rats subjected to ischemia/reperfusion injury.
Why the study?
Does the combination of vildagliptin and ischemic postconditioning reduce myocardial infarct size and improve mitochondrial and autophagic function in diabetic rats subjected to ischemia/reperfusion injury?
Does the combination of vildagliptin and ischemic postconditioning reduce myocardial infarct size and improve mitochondrial and autophagic function in diabetic rats subjected to ischemia/reperfusion injury?
Effect estimate: 48.18% reduction
p-value: p=<0.001
The combination of vildagliptin and ischemic postconditioning synergistically reduces myocardial ischemia/reperfusion injury in diabetic rats by restoring mitochondrial function and modulating autophagy.
Purpose: Diabetic hearts are resistant to cardioprotection by ischemic-postconditioning (IPostC). Protection of diabetic hearts and finding related interfering mechanisms would have clinical benefits. This study investigated the combination effects of vildagliptin (Vilda) and IPostC on cardioprotection and the levels of autophagy and mitochondrial function following myocardial ischemia/reperfusion (I/R) injury in type-II diabetic rats. Methods: Diabetes was established by high fat diet/low dose of streptozotocin and lasted for 12 weeks. The diabetic rats received Vilda (6 mg/kg/day, orally) for one month before I/R. Myocardial regional ischemia was induced through the ligation of left coronary artery, and IPostC was applied immediately at the onset of reperfusion. The infarct size was assessed by a computerised planimetry and left ventricles samples were harvested for cardiac mitochondrial function studies (ROS production, membrane potential and staining) and western blotting was used for determination of autophagy markers. Results: None of Vilda or IPostC but combination of them could significantly reduce the infarct size of diabetic hearts, comparing to control (P<0.001). IPostC could not significantly affect p62 expression level in diabetic hearts, but pre-treatment with Vilda alone (p<0.05) and in combination with IPostC (p<0.01) more significantly decreased p62 expression in comparison with corresponding control group. The expression of LC3B-II and LC3BII/LC3BI as well as mitochondrial ROS production were decreased significantly in treatment groups (p<0.001). Mitochondrial membrane depolarization was significantly higher and mitochondrial density was lower in untreated diabetic I/R hearts than treated groups (p<0.001). IPostC in combination with vildagliptin prevented the mitochondrial membrane depolarization and increased the mitochondrial content more potent than IPostC alone in diabetic hearts. Conclusion: Combination of vildagliptin and IPostC in diabetic hearts was a well-working strategy to reduce myocardial I/R damages by restoring mitochondrial membrane potential and ROS production and modulating the autophagic activity in I/R hearts.
No takes yet. Share an insight, caveat, or question.
Bayrami et al. (2018) studied Type-II diabetes with myocardial ischemia/reperfusion injury. Vildagliptin and Ischemic Postconditioning (IPostC) vs. Diabetic control (ischemia/reperfusion without treatment) was evaluated on Myocardial infarct size (percentage of left ventricular risk zone) (48.18% reduction, p=<0.001). The combination of vildagliptin and ischemic postconditioning significantly reduced myocardial infarct size by up to 48.18% compared to diabetic control in rats subjected to ischemia/reperfusion injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: